Andrew Wachtel

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials

Mark T. Dransfield, Jean Bourbeau, Paul Jones et al. · The Lancet Respiratory Medicine · 2013 · 359 citations

Medicine, Internal Medicine, Pharmacotherapy +13

Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD

Courtney Crim, Mark T. Dransfield, Jean Bourbeau et al. · Annals of the American Thoracic Society · 2014 · 155 citations

Medicine, Clinical Sciences, Pharmacotherapy +17

Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial

Gary T. Ferguson, J. Mark FitzGerald, Eugene R. Bleecker et al. · The Lancet Respiratory Medicine · 2017 · 123 citations

Pharmacy, Pharmacology, Pharmacotherapy +7

Diagnosis of Non-small Cell Lung Cancer for Early Stage Asymptomatic Patients

Cherylle Goebel, Christopher Louden, Robert J. McKenna et al. · Cancer Genomics & Proteomics · 2019 · 93 citations · Full text

Medicine, Oncology, Cancer Screening +16

Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: A randomized controlled trial

Edward Kerwin, Andrew Wachtel, Lawrence Sher et al. · Respiratory Medicine · 2018 · 19 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17